{"id":67230,"date":"2026-06-03T19:39:54","date_gmt":"2026-06-03T11:39:54","guid":{"rendered":"https:\/\/flcube.com\/?p=67230"},"modified":"2026-06-03T19:39:55","modified_gmt":"2026-06-03T11:39:55","slug":"huahai-pharmaceutical-receives-nmpa-approval-for-dual-target-ipf-therapy-hb0056-adding-to-global-clinical-trial-authorizations","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67230","title":{"rendered":"Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Zhejiang Huahai Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600521:SHA\">SHA: 600521<\/a>) announced it has received <strong>clinical trial approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>HB0056<\/strong>, a novel dual-target therapy for <strong>idiopathic pulmonary fibrosis (IPF)<\/strong> that simultaneously inhibits <strong>thymic stromal lymphopoietin (TSLP)<\/strong> and <strong>interleukin-11 (IL-11)<\/strong> receptors.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The regulatory green light completes HB0056&#8217;s <strong>global clinical trial authorization triad<\/strong>, following previous approvals in <strong>New Zealand<\/strong> and the <strong>United States<\/strong>, positioning Huahai to conduct synchronized international development of this innovative approach targeting two key pathogenic pathways in one of respiratory medicine&#8217;s most challenging conditions.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-global-development-status\" class=\"wp-block-heading\">Regulatory Milestone &amp; Global Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521)<\/td><\/tr><tr><td><strong>Regulatory Agency<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Idiopathic pulmonary fibrosis (IPF)<\/td><\/tr><tr><td><strong>Global Approvals<\/strong><\/td><td>New Zealand, United States, China (complete triad)<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Preclinical completed, clinical trials authorized globally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-novel-dual-target-mechanism-of-action\" class=\"wp-block-heading\">Novel Dual-Target Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Targets<\/strong>: Thymic stromal lymphopoietin (TSLP) receptor and interleukin-11 (IL-11) receptor<\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: Simultaneous blockade of two distinct pathogenic pathways driving IPF progression<\/li>\n\n\n\n<li><strong>Pathway Inhibition<\/strong>:<\/li>\n\n\n\n<li>Abnormal inflammatory responses via TSLP pathway<\/li>\n\n\n\n<li>Fibrotic progression via IL-11 signaling cascade<\/li>\n\n\n\n<li><strong>Clinical Advantage<\/strong>: Comprehensive disease modification addressing both inflammatory and fibrotic components of IPF<\/li>\n\n\n\n<li><strong>Innovation<\/strong>: First-in-class dual TSLP\/IL-11 inhibition strategy for pulmonary fibrosis<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-idiopathic-pulmonary-fibrosis-market-context\" class=\"wp-block-heading\">Idiopathic Pulmonary Fibrosis Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Disease Parameter<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Patient Population<\/strong><\/td><td>Estimated 3 million globally, with significant prevalence in aging populations<\/td><\/tr><tr><td><strong>Current Therapies<\/strong><\/td><td>Limited to pirfenidone and nintedanib with modest efficacy and significant side effects<\/td><\/tr><tr><td><strong>Unmet Need<\/strong><\/td><td>High mortality (median survival 3-5 years), progressive decline despite current treatments<\/td><\/tr><tr><td><strong>Treatment Gap<\/strong><\/td><td>No therapies address both inflammatory initiation and fibrotic progression simultaneously<\/td><\/tr><tr><td><strong>Market Opportunity<\/strong><\/td><td>Premium pricing potential for disease-modifying therapy with superior efficacy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications-for-huahai-pharmaceutical\" class=\"wp-block-heading\">Strategic Implications for Huahai Pharmaceutical<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation Transition<\/strong>: Demonstrates successful evolution from generic manufacturer to innovative drug developer<\/li>\n\n\n\n<li><strong>Global Ambitions<\/strong>: Synchronized international clinical development supports worldwide commercial aspirations<\/li>\n\n\n\n<li><strong>Pipeline Diversification<\/strong>: Expands beyond cardiovascular and CNS franchises into high-value respiratory therapeutics<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: First-mover advantage in dual TSLP\/IL-11 inhibition for IPF<\/li>\n\n\n\n<li><strong>Partnership Potential<\/strong>: Strong mechanism and global development may attract international pharmaceutical partnerships<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-development-strategy\" class=\"wp-block-heading\">Clinical Development Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trial Design<\/strong>: Likely multinational Phase II\/III studies leveraging all three approved jurisdictions<\/li>\n\n\n\n<li><strong>Patient Recruitment<\/strong>: Access to large Chinese IPF population accelerates enrollment timelines<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: Potential for accelerated approval based on novel mechanism and high unmet need<\/li>\n\n\n\n<li><strong>Endpoint Selection<\/strong>: May include lung function preservation, symptom improvement, and mortality reduction<\/li>\n\n\n\n<li><strong>Combination Potential<\/strong>: Future studies may explore combination with existing antifibrotics for enhanced efficacy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-analysis\" class=\"wp-block-heading\">Competitive Landscape Analysis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current IPF Market<\/strong>: Dominated by two antifibrotic agents with limited efficacy and tolerability issues<\/li>\n\n\n\n<li><strong>Pipeline Competition<\/strong>: Several companies developing novel mechanisms but few with dual-pathway approaches<\/li>\n\n\n\n<li><strong>Differentiation Factors<\/strong>: Simultaneous TSLP\/IL-11 inhibition addresses broader disease biology than single-target agents<\/li>\n\n\n\n<li><strong>Clinical Benchmark<\/strong>: Success would represent significant advance over current standard of care<\/li>\n\n\n\n<li><strong>Market Entry Timing<\/strong>: Favorable window before next-generation competitors reach market<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-considerations\" class=\"wp-block-heading\">Commercial Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pricing Strategy<\/strong>: Premium pricing justified by novel mechanism and potential disease-modifying effects<\/li>\n\n\n\n<li><strong>Market Access<\/strong>: Orphan-like status in some markets may support favorable reimbursement<\/li>\n\n\n\n<li><strong>Physician Education<\/strong>: Requires messaging on dual-pathway rationale and comprehensive disease modification<\/li>\n\n\n\n<li><strong>Patient Identification<\/strong>: Diagnostic challenges in IPF may require investment in awareness and testing infrastructure<\/li>\n\n\n\n<li><strong>Global Commercialization<\/strong>: May pursue partnership for Western markets while retaining China rights<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for HB0056. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/600521_20260603_BHG0.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600521_20260603_BHG0.\"><\/object><a id=\"wp-block-file--media-d9696dfb-d141-42fb-b769-c63486e46dd8\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/600521_20260603_BHG0.pdf\">600521_20260603_BHG0<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/600521_20260603_BHG0.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-d9696dfb-d141-42fb-b769-c63486e46dd8\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced it has received clinical trial approval from&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,775,24,1381],"class_list":["post-67230","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-huahai-pharmaceutical","tag-rare-orphan-disease-drugs","tag-sha-600521"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for HB0056, a novel dual-target therapy for idiopathic pulmonary fibrosis (IPF) that simultaneously inhibits thymic stromal lymphopoietin (TSLP) and interleukin-11 (IL-11) receptors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67230\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations\" \/>\n<meta property=\"og:description\" content=\"Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for HB0056, a novel dual-target therapy for idiopathic pulmonary fibrosis (IPF) that simultaneously inhibits thymic stromal lymphopoietin (TSLP) and interleukin-11 (IL-11) receptors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67230\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-03T11:39:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-03T11:39:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67230#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67230\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations\",\"datePublished\":\"2026-06-03T11:39:54+00:00\",\"dateModified\":\"2026-06-03T11:39:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67230\"},\"wordCount\":582,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Huahai Pharmaceutical\",\"Rare \\\/ orphan disease drugs\",\"SHA: 600521\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67230#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67230\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67230\",\"name\":\"Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-03T11:39:54+00:00\",\"dateModified\":\"2026-06-03T11:39:55+00:00\",\"description\":\"Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for HB0056, a novel dual-target therapy for idiopathic pulmonary fibrosis (IPF) that simultaneously inhibits thymic stromal lymphopoietin (TSLP) and interleukin-11 (IL-11) receptors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67230#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67230\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67230#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations - Insight, China&#039;s Pharmaceutical Industry","description":"Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for HB0056, a novel dual-target therapy for idiopathic pulmonary fibrosis (IPF) that simultaneously inhibits thymic stromal lymphopoietin (TSLP) and interleukin-11 (IL-11) receptors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67230","og_locale":"en_US","og_type":"article","og_title":"Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations","og_description":"Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for HB0056, a novel dual-target therapy for idiopathic pulmonary fibrosis (IPF) that simultaneously inhibits thymic stromal lymphopoietin (TSLP) and interleukin-11 (IL-11) receptors.","og_url":"https:\/\/flcube.com\/?p=67230","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-03T11:39:54+00:00","article_modified_time":"2026-06-03T11:39:55+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67230#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67230"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations","datePublished":"2026-06-03T11:39:54+00:00","dateModified":"2026-06-03T11:39:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67230"},"wordCount":582,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Huahai Pharmaceutical","Rare \/ orphan disease drugs","SHA: 600521"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67230#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67230","url":"https:\/\/flcube.com\/?p=67230","name":"Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-03T11:39:54+00:00","dateModified":"2026-06-03T11:39:55+00:00","description":"Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for HB0056, a novel dual-target therapy for idiopathic pulmonary fibrosis (IPF) that simultaneously inhibits thymic stromal lymphopoietin (TSLP) and interleukin-11 (IL-11) receptors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67230#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67230"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67230#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67230"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67230\/revisions"}],"predecessor-version":[{"id":67233,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67230\/revisions\/67233"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}